Find Reports
Select Report Type
Reimbursement Review
Displaying 1401 - 1422 of 1422
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| pasireotide | Signifor LAR | pasireotide | Acromegaly, adults | Active | SR0859-000 | ||||
| garadacimab | TBC | garadacimab | Hereditary angioedema (HAE) | Active | SR0860-000 | ||||
| nemolizumab | TBC | nemolizumab | Prurigo nodularis (PN) | Active | SR0861-000 | ||||
| Dabrafenib trametinib | N/A | Dabrafenib trametinib | Head and neck cancer | Active | PX0373-000 | ||||
| regorafenib | N/A | regorafenib | Metastatic osteosarcoma | Active | PX0374-000 | ||||
| relugolix, estradiol, and nore... | Myfembree | relugolix, estradiol, and norethindrone acetate | Management of heavy menstrual bleeding associated with uterine fibroids | Active | SR0885-000 | ||||
| dupilumab | Dupixent | dupilumab | Chronic rhinosinusitis with nasal polyps | Active | SR0878-000 | ||||
| risperidone | Okedi | risperidone | Schizophrenia, adults | Active | SR0879-000 | ||||
| mirikizumab | Omvoh | mirikizumab | Crohn’s disease | Active | SR0880-000 | ||||
| dabrafenib trametinib | TBC | dabrafenib trametinib | Pediatric low grade glioma (ped LGG) | Active | PX0375-000 | ||||
| guselkumab | Tremfya | guselkumab | Crohn’s disease | Active | SR0882-000 | ||||
| empagliflozin | Jardiance | empagliflozin | Chronic kidney disease | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0040-000 | |||
| tofersen | Qalsody | tofersen | Amyotrophic lateral sclerosis (ALS) | Active | SR0883-000 | ||||
| odevixibat | Bylvay | odevixibat | Alagille syndrome | Active | SR0884-000 | ||||
| talazoparib | Talzenna | talazoparib | Metastatic castration-resistant prostate cancer | Active | PC0417-000 | ||||
| risankizumab | Skyrizi | risankizumab | Ulcerative colitis | Active | SR0890-000 | ||||
| efanesoctocog alfa | Altuviiio | efanesoctocog alfa | congenital factor VIII deficiency | Active | ST0840-000 | ||||
| ruxolitinib | Opzelura | ruxolitinib | Nonsegmental vitiligo | Active | SR0835-000 | ||||
| trofinetide | Daybue | trofinetide | Rett syndrome (RTT) | Active | SR0829-000 | ||||
| rozanolixizumab | Rystiggo | rozanolixizumab | Generalized myasthenia gravis (gMG) | Active | SR0846-000 | ||||
| setmelanotide | Imcivree | setmelanotide | Weight management for pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0041-000 | |||
| pegunigalsidase alfa | TBC | pegunigalsidase alfa | Fabry disease | Received | SR0872-000 |
Health Technology Review
Displaying 576 - 600 of 600
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1401 - 1425 of 2132
Please scroll or swipe to the right to view the full content.